恆指跌幅擴至逾230點 百威、創科及藥明生物續挫4%至6%
繼聯儲局理事佈雷維德發出「鷹派」言論後,聯儲局會議紀錄也發出強烈「鷹派」信號,擬5月起啓動縮表,官員傾向多次加息0.5釐,並將每月縮減資產負債表上限增至950億美元,力度之猛遠超市場預期,美股三大指數隔晚(6日)下跌,納指挫逾2%最傷。亞太區主要股市今早(7日)普遍受壓,尤其是日經續跌1.7%;滬深股市半日跌1%至1.2%。
恆指兩連跌,今早在新經濟股主導低開170點或近0.8%,報21,910,在美團(03690.HK)等帶動掉頭曾倒升156點或0.7%,高見22,236無以爲繼,再度走低,最低見21,788,現報21,844,續吐235點或1.1%,成交額625億元。
藍籌股普遍受壓,尤其是藥明生物(02269.HK)兩連跌兼失守10天線,報64.45元,續挫6.1%;百威亞太(01876.HK)三連跌兼創約四個月低,現報19.2元,挫5.9%;創科(00669.HK)兩連跌挫兼失守上月中旬所創52周低位112.1元,最低見110.2元,現報111.3元,續挫近4%。
地產股以恆隆地產(00101.HK)沽壓最大,報16.08元,回吐3.9%;碧桂園(02007.HK)跌逾2%,報6.36元。
兩大手機設備股舜宇(02382.HK)及瑞聲(02018.HK)反覆續跌1.7%至3.5%。阿裏巴巴(09988.HK)、網易(09999.HK)及京東(09618.HK)續跌近2%至3%;另騰訊(00700.HK)反覆續跌約1%,報377.2元。
然而,美團今早再跌2%,低見157.6元(接近10天線)獲承接,掉頭曾倒升逾7%高見172.5元遇阻,現報163.4元,倒升1.6%。李寧(02331.HK)反覆回升1.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.